Recombinant Human Claudin-18.2 (CLDN18.2)-VLPs (Active)

Claudin-18.2 has emerged as a high-priority therapeutic target in oncology due to its restricted expression pattern and tumor-specific accessibility, yet its four-transmembrane topology makes recombinant production notoriously difficult. This virus-like particle (VLP) format presents full-length human CLDN18.2 (aa 1–261, isoform A2) in a membrane-embedded conformation produced in mammalian cells, preserving native folding of the extracellular loops critical for antibody recognition. Functional ELISA confirms that immobilized VLPs bind an anti-CLDN18.2 recombinant monoclonal antibody with an EC50 of 5.2–9.3 ng/ml, directly supporting antibody development, screening campaigns, and epitope-mapping studies targeting this conformational antigen. With endotoxin levels below 1.0 EU/μg, this preparation aligns with standards expected in tumor metastasis research workflows and cell-based binding assays where immune cell trafficking or adhesion mechanisms are under investigation.